These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12025892)

  • 1. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.
    Ustün C; Beksac M; Dalva K; Koc H; Konuk N; Ilhan O; Ozcan M; Topcuoglu P; Sertkaya D; Hayran M
    Med Oncol; 2002; 19(1):59-67. PubMed ID: 12025892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
    Bassan R; Chiodini B; Lerede T; Giussani U; Oldani E; Buelli M; Rossi A; Viero P; Rambaldi A; Barbui T
    Hematol J; 2002; 3(4):193-200. PubMed ID: 12189565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
    Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
    Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
    Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
    Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
    van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
    Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.
    Bolaños-Meade J; Karp JE; Guo C; Sarkodee-Adoo CB; Rapoport AP; Tidwell ML; Buddharaju LN; Chen TT
    Leuk Res; 2003 Apr; 27(4):313-21. PubMed ID: 12531222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.
    Lamy T; Drenou B; Grulois I; Fardel O; Jacquelinet C; Goasguen J; Dauriac C; Amiot L; Bernard M; Fauchet R
    Leukemia; 1995 Sep; 9(9):1549-55. PubMed ID: 7658724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
    Schlenk RF; Fröhling S; Hartmann F; Fischer JT; Glasmacher A; del Valle F; Grimminger W; Götze K; Waterhouse C; Schoch R; Pralle H; Mergenthaler HG; Hensel M; Koller E; Kirchen H; Preiss J; Salwender H; Biedermann HG; Kremers S; Griesinger F; Benner A; Addamo B; Döhner K; Haas R; Döhner H;
    Leukemia; 2004 Nov; 18(11):1798-803. PubMed ID: 15385923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
    Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
    Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
    Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
    Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
    Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-treatment with all-trans retinoic acid accelerates polymorphonuclear recovery after chemotherapy in patients with acute promyelocytic leukemia.
    Visani G; Tosi P; Cenacchi A; Manfroi S; Gamberi B; Ottaviani E; Tura S
    Leuk Lymphoma; 1994 Sep; 15(1-2):143-7. PubMed ID: 7858492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
    Baek JH; Sohn SK; Kim DH; Kim JG; Yang DH; Kim YK; Lee JJ; Kim HJ
    Acta Haematol; 2007; 117(2):109-14. PubMed ID: 17135724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.